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CalciﬁcationValve interstitial cells (VICs) are essential for valvular pathogenesis. However, the transcriptional proﬁles and
cellular functions of human aortic VICs (hAVICs) and mitral VICs (hMVICs) have not been directly compared.
We performed NimbleGen gene expression proﬁling analyses of hAVICs and hMVICs. Seventy-eight known
genes were differentially expressed between hAVICs and hMVICs. Higher expression of NKX2-5, TBX15,
OGN, OMD, and CDKN1C and lower expression of TBX5, MMP1, and PCDH10 were found in hAVICs compared
to hMVICs. The differences in these genes, excepting OGN and OMD, remained in rheumatic VICs. We also
compared cell proliferation, migration, and response to mineralization medium. hMVICs proliferated more
quickly but showed more calcium deposition and alkaline phosphatase activity than hAVICs after culture in
mineralization medium, indicating that hMVICs were more susceptible to in vitro calciﬁcation. Our ﬁndings
reveal differences in the transcription proﬁles and cellular functions of hAVICs and hMVICs.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Valvular heart disease continues to occur in a large number of
patients. The overall age-adjusted prevalence is estimated to be 2.5%
globally [1]. Themajority of the disease processes affecting heart valves
have an increased predilection for the left-sided valves [2]. Further-
more, differences exist between aortic and mitral valve disease. Rheu-
matic mitral stenosis and degenerative mitral regurgitation are the
most frequent etiologies of mitral valve disease in developing and
developed countries, respectively [3,4]. Meanwhile, calciﬁc aortic
stenosis has become the most frequent form of aortic valve disorder
and the most frequent indication for valve replacement in developed
countries [5].
The aortic semilunar valve and the bicuspid valve are both com-
prised of three layers, including the ventricularis/atrialis, spongiosa,
and ﬁbrosa. These three layers are covered by endothelial cells with
intervening valve interstitial cells (VICs) that function in homeostasis
and disease [6,7]. VICs are the most abundant cell types in heart valves
[8]. Pathological studies of diseased valves in human patients have
demonstrated that VICs are involved in the pathological processes
associated with leaﬂet thickening, collagen ﬁber disorganization, and
calciﬁcation [9,10]. The differentiation of VICs into an osteoblast-like
phenotype is believed to be an important mechanism by which valveepositedwith theGEOdatabase
ng).
rights reserved.calciﬁcation occurs [11]. Calciﬁcation occurs more frequently in the
left-sided heart valves, but the role of VICs in aortic or mitral valve
calciﬁcation remains unknown.
Valvulogenesis beginswith the formation of endocardial cushions in
the atrioventricular canal and outﬂow tract during heart development
[12]. Cell lineage studies have demonstrated that the majority of the
cells present in the valve after birth are of endocardial cushion origin
[13]. By identifying the expression of myoﬁbroblast markers, Roy et al.
were the ﬁrst to suggest that molecular differences exist among
human VICs isolated from aortic, pulmonary, mitral, and tricuspid
valves [14]. However, the transcriptional proﬁles and cellular functions
of human aortic valve interstitial cells (hAVICs) and mitral valve inter-
stitial cells (hMVICs) have not been directly compared.
In the present study, we compared the transcriptional proﬁles of
hAVICs and hMVICs using cDNAmicroarray analysis. We further exam-
ined their cellular functions including proliferation, wound repair, and
induced calciﬁcation to identify heterogeneities between these two
VIC populations.
2. Results
2.1. Differential gene expression in hAVICs and hMVICs
We assessed differential gene expression in hAVICs versus hMVICs
to determine the distinct genetic proﬁles of these VIC types. Gene
expression data of hAVICs and hMVICs were analyzed after ﬁltering
and normalization. A total of 88 genes were identiﬁed as differentially
expressed by a factor of at least 2 between hAVICs and hMVICs.
Among these 88 genes, 78 were known and 10 were novel. The 78
Fig. 1. Differential gene expression in hAVICs and hMVICs. Hierarchical cluster analysis of 78 genes expressed differentially between hAVICs and hMVICs. The expression levels are
indicated by the increased gradient of dark green to light green to red intensity.
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heat map (Fig. 1). Of the 88 differentially expressed genes, 53 were
more highly expressed in hAVICs, and 35 were more highly expressed
in hMVICs (Table S1).
2.2. Differential expression of cardiac transcription factors, bone-related
genes, and cell cycle genes in hAVICs and hMVICs
The genes that were most differentially expressed among all dif-
ferentially expressed genes were two cardiac-speciﬁc transcription
factors, NKX2-5 and TBX5. We performed quantitative real-time PCR
and Western blotting to validate the mRNA and protein levels of
these two transcription factors in hAVICs and hMVICs. The mRNA
level of NKX2-5 was 11.8-fold higher in normal hAVICs than in normal
hMVICs and 39.6-fold higher in rheumatic hAVICs than in rheumatic
hMVICs (Fig. 2A). However, the mRNA level of TBX5 was 58.1-fold
lower in normal hAVICs than in normal hMVICs, and 228.0-fold lower
in rheumatic hAVICs than in rheumatic hMVICs (Fig. 2B). The mRNA
levels of both NKX2-5 and TBX5 signiﬁcantly decreased in rheumatic
hAVICs and hMVICs. The protein level of NKX2-5 was 1.7-fold higher
in normal hAVICs than in normal hMVICs (Figs. 3A–B). The protein
level of TBX5 was 3.0-fold higher in normal hMVICs than in normal
hAVICs (Figs. 3C–D).
After categorizing the differentially expressed genes according to
GO function, we found that several genes associated with bone and
cartilage development and one cell cycle gene were more highly
expressed in hAVICs versus hMVICs (Table S2). The gene with the
highest increase in expression in normal hAVICs was the T box tran-
scription factor TBX15, followed by osteoglycin (OGN), CDKN1C
(P57Kip2), and osteomodulin (OMD). The other two extracellular matrix
genes,MMP1 and PCDH10, have signiﬁcantly lower expression levels in
normal hAVICs. Validation of the expression of these six genes with
quantitative real-time polymerase chain reaction (PCR) revealed a
4.5-fold higher expression of TBX15, 3.9-fold higher expression of
OGN, 3.1-fold higher expression of CDKN1C, 2.2-fold higher expression
of OMD, 7.2-fold lower expression of PCDH10, and 8.4-fold lower
expression ofMMP1 in hAVICs versus hMVICs (Fig. 2C). Further valida-
tion of these genes was performed in rheumatic VICs and revealed a3.7-fold higher expression of TBX15, 2.1-fold higher expression of
CDKN1C, 2.3-fold lower expression of OGN, 1.3-fold lower expression
of OMD, 3.3-fold lower expression of PCDH10, and 7.2-fold lower
expression of MMP1 in rheumatic hAVICs versus rheumatic hMVICs.
The expression levels of TBX15, OGN, CDKN1C, and OMD signiﬁcantly
decreased in rheumatic hAVICs and hMVICs. However, MMP1 and
PCDH10 expression signiﬁcantly increased in rheumatic hAVICs and
hMVICs (Fig. 2C).
2.3. Migration and proliferation of hAVICs and hMVICs
We further compared the migration and proliferation abilities of
hAVICs and hMVICs. At 12 and 24 h after wounding, hAVIC wounds
showed a similar extent of wound closure compared to hMVIC wounds
(Figs. 4A–G). During the MTS assay performed during a 12-day contin-
uous culture, hMVICs showed greater proliferation than hAVICs,
starting from the fourth day (Fig. 5A). The greater proliferation of
hMVICs was further conﬁrmed by an additional assay using EdU stain-
ing (Figs. 5B–C). These results indicate similar migration abilities but
different proliferation rates between hAVICs and hMVICs.
2.4. hMVICs are more susceptible to in vitro calciﬁcation than hAVICs
Because several bone-related genes were more highly expressed
in hAVICs, we examined the responses of hAVICs and hMVICs to min-
eralization media-induced calciﬁcation. After 14 days in culture, the
intensity of Alizarin red staining in hMVICs was greater than the
staining in hAVICs (Fig. 6A). In addition, the mRNA level and activity
of ALP in hMVICs were higher compared to hAVICs (Figs. 6B, C). We
further examined the expression of TBX15, OGN, OMD, MMP1,
NKX2-5, and TBX5 after induced calciﬁcation. The expression levels
of TBX15, OGN, MMP1, NKX2-5, and TBX5 were signiﬁcantly decreased
in hAVICs and hMVICs, but the expression level of OMD increased after
induced calciﬁcation. Differences in TBX15, NKX2-5, and TBX5 expres-
sion were observed between hAVICs and hMVICs after induced calciﬁ-
cation (Figs. 7A–C). To compare the difference of osteogenic
differentiation between hAVICs and hMVICs, the expression levels of
osteogenic marker genes including OCN(BGLAP), OPN(SPP1), BSP(IBSP),
Fig. 2. Differentially expressed genes validated with quantitative real-time PCR. The expression of each gene in hAVICs and hMVICs is shown as the fold change based on the relative
expression level of the given gene in hAVICs or hMVICs to the average value derived from the control gene. A)NKX2-5wasmore highly expressed in hAVICs and downregulated in rheu-
matic hAVICs and hMVICs. B) TBX5was more highly expressed in hMVICs and downregulated in rheumatic hAVICs and hMVICs. C) Among these genes, TBX15 and CDKN1Cwere more
highly expressed in both normal and rheumatic hAVICs and downregulated in rheumatic hAVICs and hMVICs. OGN and OMDwere highly expressed in normal hAVICs, but had a lower
expression in rheumatic hAVICs.MMP1 and PCDH10were more highly expressed in hMVICs and upregulated in rheumatic hAVICs and hMVICs. *P b 0.05. N — normal, R — rheumatic.
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was highly expressed in hMVICs compared to hAVICs (Figs. 8A–D). Ap-
optosis is involved in valve/VIC calciﬁcation in vitro. Therefore, we com-
pared the expression levels of apoptosis-associated genes including
CASPASE-3(CASP3), FAS, and BCL2 between hAVICs and hMVICs after in-
duced calciﬁcation. No signiﬁcant differences were observed between
hAVICs and hMVICs (Figs. 8E–G).
3. Discussion
Although most hAVICs and hMVICs are of endothelial endocardial
cushion origin, there are different blood ﬂow dynamics of the aortic
and mitral valves. Therefore, in adults, differences between hAVICs
and hMVICs likely exist. The molecular regulation described for aortic
VICs should not be considered the same as for mitral VICs. To our
knowledge, no report has concentrated on validating the transcrip-
tional differences between hAVICs and hMVICs. In this study, we
characterized the heterogeneity between hAVICs and hMVICs by
studying their transcriptional proﬁles and cellular functions.
Among genes that were more highly expressed in hAVICs com-
pared to hMVICs, the homeodomain transcription factor NKX2-5
showed the greatest difference and was validated by quantitativereal-time PCR and Western blotting. NKX2-5 is an important tran-
scriptional regulator during early embryonic heart development and
is essential for development of the conduction system [15]. NKX2-5
mutations are often observed in patients with familial congenital
heart defects, such as atrial septal defects and ventricular septal
defects. The most common defect in patients with NKX2-5 mutations
or heterozygous NKX2-5-null mice is an atrial septal defect, with or
without atrioventricular block [15,16]. Approximately 10% of hetero-
zygous NKX2-5-null mice show aortic valve dysmorphogenesis, but
not pulmonary or mitral valve abnormalities, on the C57Bl/6 back-
ground [16]. However, a human study failed to demonstrate a direct
association between bicuspid aortic valve malformation and the
NKX2-5 mutation, as was observed in mice [17]. Our results showing
a high expression ofNKX2-5 in hAVICs,with the valve defect restricted to
the aortic valve in NKX2-5 mutant mice, suggest a relationship between
NKX2-5 and formation of the normal aortic valve. The effect of NKX2-5
on hAVICs and the adult aortic valve should be studied further.
Another transcription factor, TBX5, is speciﬁcally expressed in
hMVICs. TBX5, a member of the T-box transcription factor gene fam-
ily, is very important for cardiogenesis; mutations in TBX5 cause
Holt–Oram syndrome [18,19]. Defects in atrial and ventricular
septation are most prevalent in Holt–Oram syndrome, but additional
Fig. 3. Differential expression of the cardiac-speciﬁc transcription factors Nkx2-5 and TBX5 in hAVICs and hMVICs. A–B) Western blot of Nkx2-5 showed that the protein level of
Nkx2-5 was higher in hAVICs than that in hMVICs. *P b 0.01. C–D) On the contrary, the protein level of TBX5 in hAVICs was signiﬁcantly lower than that in hMVICs. **P b 0.001.
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nized. TBX5 expression in developing atrioventricular valves and
ventricular trabeculae (which contribute to chordae tendineae) likely
accounts for the structural and functional defects in mitral and tricus-
pid valves [20–22]. The high expression of TBX5 in hMVICs suggests
that this developmental difference between hMVICs and hAVICs is
maintained in adults. TBX5 may also be a marker for differentiating
hMVICs from hAVICs. Previous studies have shown that TBX5 inhibits
embryonic cell proliferation [23]. But the loss of TBX5 function study
did not support a negative role for TBX5 in growth regulation [24].
Georges et al. have demonstrated that TBX5 performs distinct function
through two alternatively spliced isoforms. The long isoform correlates
with cell proliferation and the upregulation of short isoform (C-terminal
truncated form) leads to growth arrest. The long isoform is predominant
in proliferating C2C12 myoblasts [25]. In the present study, long-
isoform TBX5 was highly expressed in hMVICs, and these cells prolifer-
atedmore quickly than hAVICs (which express TBX5 at very low levels).
Our results are consistent with previous reports and suggest a high per-
centage of the long-isoform TBX5 in hMVICs which contributes to their
faster proliferation.
In this study, CDKN1Cwas highly expressed in hAVICs compared to
hMVICs. Accordingly, hAVICs proliferate more slowly than hMVICs.
CDKN1C expression was also signiﬁcantly decreased in rheumatic
hAVICs. These data suggest that CDKN1C affects hAVIC proliferation.
CDKN1C is a cyclin-dependent kinase (CDK) inhibitor belonging to the
Cip/Kip family. As a CDK inhibitor, CDKN1C is highly expressed in the
G0 to G1 phases of the cell cycle and decreases during the progression
from G1 to S phase [26]. We speculate that the higher expression of
CDKN1C in normal hAVICs contributes to their slower proliferation,
and the decreased expression of CDKN1C in rheumatic hAVICs is related
to pathological hAVIC proliferation. Another gene, PCDH10, was highly
expressed in hMVICs and is signiﬁcantly downregulated in severaltypes of human cancer, therefore suggesting it may be a candidate
tumor suppressor gene [27,28]. In our study, PCDH10 was highly
expressed in normal and rheumatic hMVICs compared to hAVICs, but
was upregulated in rheumatic hAVICs and hMVICs. These results
suggest a potential anti-proliferation effect of PCDH10 on diseased
hAVICs and hMVICs.
Calciﬁc aortic stenosis is considered a degenerative disease in which
calcium passively accumulates on the leaﬂets of the valve. However,
some investigators suggest that the pathogenesis of calciﬁc valve steno-
sis may be an active disease process involving osteogenesis [29]. Recent
descriptive studies of calciﬁc valve disease specimens from patients
have demonstrated morphologic features resembling bone formation
as well as expression of proteins associated with bone formation
[30,31]. VICs are believed to progress toward calciﬁcation by differenti-
ating toward an osteoblast-like phenotype [11,32]. In our induced
calciﬁcation experiments, hMVICs were more susceptible to induced
calciﬁcation than hAVICs andwere characterized bymore calciumdepo-
sition, stronger ALP activity, and higher expression of COL1A1. The
expression levels of other osteogenic speciﬁc genes and apoptosis
genes such asOCN, BSP,OPN, CASPASE-3, FAS, and BCL2were comparable
between hAVICs and hMVICs. We think that the greater calciﬁcation in
hMVICs is not due to osteogenic differentiation or apoptosis-associated
calciﬁcation.
In the present study, we discovered that several bone-related genes,
including TBX15, OGN, and OMD, were highly expressed in normal
hAVICs but not in normal hMVICs. In VICs cultured in mineralization
media or isolated from rheumatic valves, OGN and OMD expression
was variable, indicating that these two factors are more susceptible to
cellular environment changes. The exact effects of these two genes
must be further identiﬁed. Calciﬁcation differences between hAVICs
and hMVICs cannot be attributed to altered expression levels of these
two genes. Moreover, TBX15 continued to be expressed at higher levels
Fig. 4. Closure of a wounded VIC monolayer after 24 h. Representative phase-contrast micrographs of wounded hAVIC (A–C) and hMVIC (D–F) monolayers. F) Measurement of the
width of the wound between the two wound edges at 0, 12, and 24 h showed no signiﬁcant differences in the closure rates between hAVICs and hMVICs (n = 3), indicating com-
parable migration abilities of these two types of VICs. The scale bar is 100 μm.
330 W. Sun et al. / Genomics 101 (2013) 326–335in hAVICs compared to hMVICs. These results imply a very interesting
heterogeneity between hAVICs and hMVICs. TBX15 is important for
skeletal development, deletion of TBX15 results in decreased SOX9Fig. 5. Proliferation of hAVICs and hMVICs. A) Comparable numbers of hAVICs and hMVICs w
greater than in hAVIC cultures from the 4th to 12th days. *P b 0.05. B–C) Using EdU imagin
observed after 5 days in low serum media culture. *P b 0.05.positive mesenchymal precursor cells and impaired chondrogenesis
[33]. TBX15 and TBX18 are closely related T Box genes and biochemical-
ly equivalent. TBX18 may counteract the activation of the negativeere seeded for the MTS assay. The relative number of viable cells in hMVIC cultures was
g proliferation assays, a greater percentage of proliferating cells in hMVIC cultures was
Fig. 6. In vitro induced calciﬁcation in hAVICs and hMVICs. A) hAVICs and hMVICs were cultured for 2 weeks in the presence of 50 μg/ml ascorbic acid, 10 mM β-glycerophosphate,
and 1 mM dexamethasone, and calciﬁcation analysis was performed with Alizarin red S staining. Quantiﬁcation of Alizarin red showed more calcium deposition in hMVICs than in
hAVICs; *P b 0.05. B) Quantitative real-time PCR showed that the mRNA level of ALP was 3.2-fold higher in hMVICs than in hAVICs. C) Stronger ALP activity was also found in
hMVICs compared to hAVICs. **P b 0.01.
331W. Sun et al. / Genomics 101 (2013) 326–335regulator of NOTCH1, Delta-like 1 (DLL1) [34]. Suppression of NOTCH1
signaling in porcine AVICs downregulates SOX9 expression and pro-
motes subsequently in vitro calciﬁcation [35]. We speculate that the
high expression of TBX15 in hAVICs attenuates the calciﬁcation through
Notch1 mediated SOX9 pathway, which needs further investigation. In
our study, we discovered that MMP1 was highly expressed in hMVICs
before, but signiﬁcantly downregulated after, culture in mineralization
media. MMP1 regulates the expression of molecules that mediate oste-
oblastic differentiation in osteogenic cells. Knockdown of MMP1 signif-
icantly increases the levels of osteoblastic markers, including RUNX2,
OPN, and OCN [36]. Because OPN and OCN levels were the same
between hAVICs and hMVICs after induced calciﬁcation, we hypothe-
size that the loss of expression of MMP1 in hMVICs is associated with
mineralization, but not attributed to the increased susceptibility of
hMIVCs to induced calciﬁcation.
The most common valves affected by the calciﬁc process, in
descending order, are the aortic, mitral, pulmonary, and tricuspid
valves. An inﬂammatory mechanism may be responsible for such
valve calciﬁcation [2]. In contrast, our study showed that hMVICs
had a greater propensity for calciﬁcation induced by mineralization
media. We speculate that different promoting factors and regulating
mechanisms for calciﬁcation may be associated with the greater calci-
ﬁcation in hMVICs. In this study, inorganic phosphate released from
β-glycerophosphate and ascorbic acid act as essential co-factors to
promote mineralization in vitro [37,38]. In clinical practice, a high
prevalence of valve calciﬁcation in patients with end-stage renal dis-
ease is associated with calcium/phosphate metabolism abnormalities
and is somewhat similar to our media-induced calciﬁcation in vitro.
In patients with end-stage renal disease, an average prevalence of
45.9% (36%–59%) and 40.4% (28%–52%) of mitral and aortic valve
calciﬁcation, respectively, has been reported, indicating a calciﬁc sus-
ceptibility of the mitral valve to mineral metabolism abnormalities
[39–43]. Thus, our results suggest that hMVICs may be more suscep-
tible to calciﬁcation associated with calcium/phosphate metabolism
abnormalities.4. Conclusions
Our ﬁndings highlight the differential expression of cardiac tran-
scription factors, bone-related genes, and cell cycle genes between
hAVICs and hMVICs and identify a potential calciﬁcation-preventing
factor, TBX15, in hAVICs. We also reveal the heterogeneities of cell
proliferation and in vitro calciﬁcation between normal hAVICs and
hMVICs.
5. Materials and methods
5.1. Ethics statement
This study was approved by the Ethics Committees of the First
Afﬁliated Hospital of Nanjing Medical University and conformed to
the principles outlined in the Declaration of Helsinki. Written informed
consent was obtained from all the donors' parents and patients.
5.2. Cell isolation and culture
Small portions of normal aortic and mitral valves were obtained
from ﬁve healthy donor hearts following the donors' deaths in trafﬁc
accidents (threemales and two females, 25 to 34 years old). All samples
were examined by gross examination, and microscopic examination of
hematoxylin and eosin-stained cryosections was conducted to conﬁrm
the absence of disease. Small portions of each valve were collected for
VIC isolation. Fifteen couples of stenotic aortic andmitral valve samples
were obtained from 15 female patients (48 ± 7 years old) who
underwent surgical valve replacement for rheumatic aortic and mitral
stenosis. Samples were divided into three groups (ﬁve couples of valves
per group) and non-calciﬁc portions of rheumatic valves from each
group were used for cell isolation.
AVICs and MVICs were isolated by collagenase digestion as previ-
ously described [44] and cultured in DMEM (Hyclone) supple-
mented with 10% fetal bovine serum (FBS; Hyclone), 1% penicillin–
Fig. 7. Differential expression of TBX15,OGN,OMD,MMP1,NKX2-5, and TBX5 after induced calciﬁcation in hAVICs and hMVICs. A) Comparison of the expression levels of TBX15, OGN, and
OMD showed that TBX15 and OGNwere signiﬁcantly downregulated in both hAVICs and hMVICs after induced calciﬁcation. OMDwas upregulated after induced calciﬁcation, but a sig-
niﬁcant difference was observed only in hMVICs. MMP1 was downregulated only in hMVICs after induced calciﬁcation. The differences in OGN, OMD, and MMP1 expression between
hAVICs and hMVICs disappeared after induced calciﬁcation. The TBX15 mRNA level remained higher in hAVICs than in hMVICs after induced calciﬁcation. B–C) NKX2-5 and TBX5
were signiﬁcantly downregulated in both hAVICs and hMVICs after induced calciﬁcation, but the differences in NKX2-5 and TBX5 expression between hAVICs and hMVICs remained.
*P b 0.01. I.C. — induced calciﬁcation.
332 W. Sun et al. / Genomics 101 (2013) 326–335streptomycin, and 2 mM L-glutamine. Primary VICs were phenotypical-
ly examined by immunostaining with primary antibodies against
vimentin (1:500, Abcam, ab45939) and α-smooth muscle actin
(1:1000, Cy3-conjugated, Sigma, C6198). Following incubation with
the primary antibodies, the sections were incubated with a secondary
Dylight TM488-conjugated donkey anti-rabbit IgG (Jackson). Primary
cells from normal valves were used for microarray analysis. Normal
cells from passages three to ﬁve were used for real-time PCR, Western
blots, proliferation assays, migration assays, and induced calciﬁcation
experiments. VICs isolated form rheumatic valves were used only for
quantitative PCR.
To induce calciﬁcation, cells were cultured in mineralization medi-
um [DMEM supplemented with 10% FBS, 1% penicillin–streptomycin,
2 mM L-glutamine, 10 mM β-glycerophosphate (Sigma), 50 μg/ml
ascorbic acid (Sigma), and 100 nM dexamethasone (Tocris)]. The ad-
dition of ascorbic acid, β-glycerophosphate, and dexamethasone to
osteogenic differentiation medium has been described previously
for multiple cell types [45,46].5.3. RNA extraction, ampliﬁcation, and labeling
Total RNA was extracted using Trizol reagent (Invitrogen) and
further puriﬁed using NucleoSpin® RNA clean-up (MACHEREY-NAGEL,
Germany) according to the manufacturer's instructions. The RNA qual-
ity was assessed with formaldehyde agarose gel electrophoresis and
quantitated spectrophotometrically. Total RNA (1 μg) was converted
to cDNA and labeled for advance microarray according to the
manufacturer's protocol (CapitalBio Corporation, Beijing, China).5.4. Microarray hybridization and data analyses
Six samples (hAVICs and hMVICs in biological triplicate) were
submitted for array hybridization at CapitalBio Corporation, China.
Brieﬂy, labeled samples were dried, reconstituted in hybridization
solution, and denatured at 95 °C for 3 min prior to loading onto themi-
croarray. Hybridization was performed at 42 °C for 14 h with the
NimbleGen hybridization system. Arrays were washed in wash
buffers I, II, and III supplied by NimbleGen and dried in the NimbleGen
microarray dryer. The arrays were scanned using an MS200
scanner (NimbleGen) with 2-μm resolution, and NimbleScan soft-
ware (NimbleGen) was used to extract raw ﬂuorescent intensity
data from the scanned images. The scanned images were checked
visually and showed no apparent chip defects or the defect area covered
less than 1% of the array. Sample Tracking Control features, which were
used to conﬁrm that the correct sample was hybridized to each array
and the experimental metrics report, which assessed the overall quality
of the microarray experiments, were also checked according to the
NimbleGen instructions. The expression data of the probes were
normalized using quantile normalization, and the expression data of
the genes were generated using the Robust Multichip Average algo-
rithm. In a comparison analysis, the two-class unpaired method in the
signiﬁcant analysis of microarray software (SAM, version 3.02) was
performed to identify signiﬁcant, differentially expressed genes
betweenhAVIC and hMVIC groups. Geneswere determined to be signif-
icantly differentially expressed if the selection threshold of a false dis-
covery rate (FDR) was b5% and the fold change in the SAM output
result was >2.0. Hierarchical clustering with the average linkage
method was performed with Cluster3.0 software, and the cluster result
Fig. 8. Osteogenic differentiation and apoptosis-associated genes validated using quantitative real-time PCR. A–D) Comparison of the expression levels of osteogenic
differentiation-associated genes including OCN, BSP, OPN, and COL1A1 showed that COL1A1 was signiﬁcantly up-regulated in hMVICs and no difference in OCN, BSP, or OPN expres-
sion between hAVICs and hMVICs was observed after induced calciﬁcation. E–G) No difference in the expression of apoptosis-associated genes, including CASPASE-3, FAS, and BCL2,
between hAVICs and hMVICs was observed after induced calciﬁcation. **P b 0.01.
333W. Sun et al. / Genomics 101 (2013) 326–335was visualized with the Treeview program. The complete data set can
be accessed in the GEO database with the accession number GSE40801.
5.5. Quantitative real-time PCR
Gene-speciﬁc primers (Table S3) were designed to span an exon–
exon junction to ensure that all of the expected PCR products were gen-
erated from mRNA. Real-time PCR was performed on an ABI 7300(Applied Biosystems) for 40 cycles with 2× SYBR Green®PCR Master
Mix (Applied Biosystems). Serial dilutions of standard cDNA prepared
from VICs were used to generate a standard curve of PCR efﬁciency.
Standard curves for NKX2-5, TBX15, OGN, OMD, CDKN1C, PCDH10,
TBX5, MMP1, OCN, BSP, OPN, COL1A1, CASPASE-3, FAS, and BCL2 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) exhibited simi-
lar slopes, allowing gene expression levels to be normalized to GAPDH
using the△△Ct method (Applied Biosystems manual). The expression
334 W. Sun et al. / Genomics 101 (2013) 326–335ratio was calculated according to the 2−△△Ct method. All measure-
ments were performed in triplicate.
5.6. Western blot
Cells were harvested after reaching conﬂuency. Cytoplasmic and
nuclear extracts were prepared with lysis buffer (2 mM PMSF,
2 mM Na3VO4, 0.5× Protease Inhibitor Cocktail Tablets without
EDTA from Roche Applied Science, 20 mM Tris–HCl pH 8.0, 100 mM
NaCl, 10% Glycerol, 50 mM NaF, 10 mM β-glycerophosphate, 5 mM
sodium pyrophosphate, 5 mM EDTA, 0.5 mM EGTA, 1% NP-40). Protein
concentrations were determined with a bicinchoninic acid protein
assay (Thermo). Cell lysates were resolved with 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and transferred onto a
polyvinylidene diﬂuoride membrane. The membrane was probed with
anti-GAPDH mouse antibody (loading control) and goat anti-mouse
secondary antibody (1:5000; Santa Cruz Biotechnology, Inc. [for
both]), rabbit anti-Nkx2-5 antibody (1:200; Santa Cruz Biotechnolo-
gy, Inc., H-114), and goat anti-TBX5 antibody (1:200; Santa Cruz Bio-
technology, Inc., C-20) followed by goat anti-rabbit or mouse
anti-goat secondary antibody (1:5000, Santa Cruz Biotechnology,
Inc.). The blots were developed with enhanced chemiluminescence
(ECL) reagent (Thermo) and exposed on a ChemiDoc MP imager
(Bio-Rad). Image Lab™ software was used to quantify band density.
All blots were carried out independently at three times.
5.7. Wound healing experiments
hAVICs and hMVICs were grown in six-well culture dishes. After
reaching conﬂuency, cells were cultured with serum free medium
for 24 h. Then, a 200-μl tip was used to make a linear wound across
the conﬂuent monolayer. The wounded monolayer was washed three
times with a standard medium to remove cell debris, and cultured
with serum free medium. Monolayers were subsequently ﬁxed with
4% paraformaldehyde 0, 12, and 24 h after wounding. The width
between the bases of each wound edge was calculated as previously
described [47]. In all conditions, experimentswith three sets of cultured
dishes for each treatment were conducted at least in triplicate.
5.8. Proliferation assays
5.8.1. MTS assay
Cell proliferation was assessed with the CellTiter 96® AQueous one
solution cell proliferation assay kit (Promega) according to the
manufacturer's instructions. Brieﬂy, cells were seeded onto three
microtiter plates at a density of 3000 cells in 100 μl per well. Cells
were cultured in DMEM with 10% FBS for 2, 4, 6, 8, 10, and 12 days. At
each time point, MTS reagent (20 μl) was added to each well and
incubated at 37 °C for 3 h. Absorbance was recorded at 490 nm with a
microplate reader (ELx800, BioTek). All experiments were repeated
three times.
5.8.2. EdU imaging assay
Our preliminary experiments showed that human VICs did not
grow well in serum-free media (data not shown). For proliferation
assays, cells were grown on glass coverslips in DMEM with low serum
(3% FBS) for 5 days. EdU was added to the culture media in concentra-
tions of 20 μM for 24 h. After labeling, cells were washed two to three
times with phosphate-buffered saline (PBS), followed by ﬁxation for
15 min in PBS containing 3.7% formaldehyde and permeabilization for
20 min in PBS containing 0.5% TritonX-100. Cells were rinsed twice
with PBS containing 3% BSA and incubated for 1 h in Click-iT® reaction
cocktail containing Alexa Fluor® 488 (Invitrogen, diluted 1:400) to
stain EdU. After EdU staining, cells were counterstained with Hoechst
33342 (Invitrogen, diluted 1:2000) for 30 min, mounted, and imaged
using ﬂuorescence microscopy. All EdU positive cells were countedand the ratio of EdU positive cells to Hoechst positive cells was com-
pared between hAVICs and hMVICs.
5.9. Alkaline phosphatase (ALP) activity assay
After culturing in mineralization medium for 14 days, cells were
lysed and cellular ALP activity was measured with a ﬂuorometric de-
tection kit using 4-methylumbelliferyl phosphate disodium substrate
(WAKO, Japan). ALP activity of each sample was normalized to the
protein concentration.
5.10. Alizarin red S staining and quantiﬁcation
Culture dishes were washed with Ca2+-free PBS three times and
ﬁxed in 95% ethanol for 30 min. The cells were stained in 2% Alizarin
red S solution (pH 4.2) for 1 min to visualizematrix calciumdeposition.
The remaining dye was washed out with several washes of distilled
water, and the stained cells were photographed. For quantiﬁcation,
Alizarin red S stain was extracted with 10% cetylpyridinium chloride
and quantiﬁed by measuring its absorbance at 570 nm. Samples were
run in triplicate.
5.11. Statistical analyses
Statistical analyses were performed using SPSS 17.0. Data are given
as the mean ± standard deviation. Comparisons were performed with
unpaired t-test or analysis of variance between normal hAVICs and
hMVICs, or rheumatic hAVICs and hMVICs, or normal hAVICs and rheu-
matic hAVICs, or normal hMVICs and rheumatic hMVICs. P b 0.05 was
considered to indicate statistical signiﬁcance.
6. Study limitations
Because of the limited normal valve samples and the aim to explore
themost common differences between hAVICs and hMVICs, valve sam-
ples from the ﬁve donors were pooled for VIC isolation. Primary
cultured VICs were used for microarray cDNA analyses, and cultured
VICs were used for further experiments. Caution should be used when
extrapolating the data to in vivo changes. Shear stress is believed to
be an important factor for valvular calciﬁcation, especially in bicuspid
aortic valves. In this study, we only investigated the susceptibility to
in vitro induced calciﬁcation of hAVICs and hMVICs in static cultures.
The inﬂuence of shear stress on hAVIC and hMVIC calciﬁcation requires
further investigation.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2013.03.004.
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